Destruction of a destructor: a new avenue for cancer therapeutics targeting the Wnt pathway.
A new study in Nature has identified a small molecule inhibitor for the oncogenic Wnt/beta-catenin pathway that is responsible for many human cancers. This inhibitor targets an unsuspected cellular enzyme, Tankyrase, which controls the destruction of a beta-catenin destructor.
Liu
Chunming
C
Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
He
Xi
X
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D060466:Axin Protein; D006801:Humans; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy*; D012097:Repressor Proteins / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D054852:Small Molecule Libraries / Q000494:pharmacology; D038501:Tankyrases / Q000378:metabolism; D051153:Wnt Proteins / Q000378:metabolism*; D051176:beta Catenin / Q000378:metabolism
D000970:Antineoplastic Agents; D060466:Axin Protein; D012097:Repressor Proteins; D054852:Small Molecule Libraries; D051153:Wnt Proteins; D051176:beta Catenin; D038501:Tankyrases